Loading clinical trials...

A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 1NCT02567695

A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects

The purpose of this study is to evaluate the relative bioavailability of a single 300 mg dose of GBT440 administered as a high strength (1 × 300 mg) capsule versus a low strength (3 × 100 mg) capsule ...

Lead sponsor: Global Blood Therapeutics•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Related studies

RECRUITINGPhase 3

A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

NCT06612268 · Sickle Cell Disease

RECRUITING

ATHNdataset Registry

NCT06820515 · Hemophilia, Thrombosis, and more

RECRUITING

Functional Ovarian Reserve in Sickle Cell Disease

NCT07392216 · Sickle Cell Disease

RECRUITINGPhase 1

A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

NCT07187973 · Sickle Cell Disease

RECRUITING

Sickle Cell Disease and the Genomic and Gene Therapy Needs of Stakeholders

NCT04416178 · Sickle Cell Disease

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 12, 2017Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment26

Start dateSep 2015

Last updatedApr 12, 2017

Condition

Sickle Cell Disease

Locations shown

ICON Early Phase Services, LLC Clinical Research Unit

San Antonio, Texas

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 12, 2017Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects

What this study is about

Clareo turns complex medical information into clear understanding you can use.

Sponsors

Related studies

A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

ATHNdataset Registry

Functional Ovarian Reserve in Sickle Cell Disease

A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

Sickle Cell Disease and the Genomic and Gene Therapy Needs of Stakeholders

Trial snapshot

Condition

Locations shown

For caregivers